Doctors Shea and Frank suggest that although patients may improve with placebo they don't truly get better or remit. Not surprisingly, as the criterion for "re sponse" becomes more stringent, the response rate for both drugs and placebo goes down. It's not clear, how ever, that using remission rather than improvement as the endpoint enhances the drug-placebo difference.
ventional criterion of a greater than 50% improvement in Hamilton scores. In the first study (n = 125) placebo responders' mean Hamilton scores dropped from 26.5 to 7.1, in the second (n = 88) from 24.9 to 5.9 (Brown et al. 1988) and in the third (n = 241) from 27.4 to 6.1 (Brown et al. 1992) . These data come from clinical trials and may not be fully generalizable to the practice set ting. Nonetheless, they suggest that patients treated with placebo can experience substantial clinical change. Doctors Klein, Rush, and Frank suggest that one or more components of the placebo treatment situation might be as effective as the entire placebo treatment package. Dr. Klein suggests that the improvement in placebo-treated patients is accounted for by spontane ous remission. If he's correct a substantial number of depressed patients might be managed by simply in structing them to report back in a few weeks. My read ing of the data that edge up to this issue (low rate of remission in waiting list controls, low rate of remission during evaluation weeks preceding assignment to treat-ment, known effects of expectation on general treat ment outcome) is that the treatment situation in itself provides benefit beyond that from the passage of time.
But, since placebo treatment has not been directly com pared to absolutely no treatment, the contribution of spontaneous remission to the placebo response is un clear.
There seems to be a consensus that some type of nonpharmacologic minimal intervention (wait and see, extended evaluation, limited counseling) might be suffi cient management for a substantial number of depressed patients. But there is a reluctance to prescribe placebo.
This reluctance seems to arise from the absence of data supporting the therapeutic effectiveness of pill inges tion per se and the assumption that a pill identified as placebo will be unacceptable to patients.
The role of pill ingestion in the placebo response is unknown. And it will remain unknown until the in dividual components of the placebo treatment situation are dissected and evaluated along the lines suggested by Dr. Klein. At this point, we simply don't know which components of the placebo treatment situation are the "active ingredients."
As for patient acceptance, the recent report men tioned by Dr. Delbanco (Eisenberg et al. 1993 ) on the use of alternative medicine strikes me as pertinent. This survey showed that one out of three adults use alter native therapies (e.g., massage, homeopathy, spiritual healing, megavitamins), and that the number of visits per year to providers of alternative therapy is greater than the number of visits to primary care physicians.
Depression was among the five conditions for which people were more likely to seek alternative than con ventional treatment, and 35% of the depressed patients treated by physicians sought alternative therapy as well.
Neither the FDA nor the readers of this journal would be persuaded by the "evidence" offered for the efficacy of alternative treatments. But our patients flock to these treatments-and, perhaps wisely, they don't tell us about it (Eisenberg et al. 1993) . Clearly, our pa tients have different ideas than we do about what's good for them and they use diff erent criteria in selecting treat ments.
A thread that runs through alternative medicine is that the body can heal itself. A prescription for placebo treatment affrrms this belief. And, although a treatment that works in a mysterious manner may be an anathema to those of us seeking rational therapies, this very mys tery-and magic-may be not only acceptable but ap pealing to many of our patients.
As for the prescription of identified placebo sound ing like something from the Wizard of Oz or depicting psychiatrists as "artful, exploitative, manipulators who take advantage of patients' gullibility," imagine this sce nario. Your internist tells you that you have mild hyper tension and that one of your options is to take placebo pills for two months. 'We don't know how they work," your internist says, ''but about 20% of the patients with your degree of hypertension get their blood pressure into the normal range with this approach. These placebo pills have fewer side effects than any other medicine I would prescribe for you and they're less expensive.
If they don't work I'll recommend one of the standard medicines for you." Does this sound flaky, exploitative, artful?
Running through the commentaries is a concern that patients treated with placebo are deprived of treat ment that is clearly more beneficial. Drs. Klein, Dun ner, and Delbanco suspect that the clinician would be at fault if a patient suicides during placebo treatment.
A recent review of psychotropic drugs and suicide (Mann et al. 1993) indicates that although in some studies patients treated with placebo as compared to those on antidepressants have a higher incidence of sui cidal ideation, placebo treated patients do not have a higher incidence of suicide. These data come from clin ical trials, which exclude actively suicidal patients; as
I said, such patients should also be excluded from pla cebo treatment.
So much for the data. Neither conventional medical care nor the communities' perception of good medical care are based solely, or even largely, on data. I have no idea whether the data would be an adequate defense.
How good are our treatments in general? What is the patient treated with placebo being deprived of? Let's take antidepressants; they're the current standard against which other treatments are measured. Drug placebo diff erences vary depending on the patient popu lation, study methodology, and so on. Dr. Rush, on the basis of a large meta-analysis of placebo-controlled clin ical trials, has come up with a drug-placebo difference of 18 to 25%. That's not an astonishing drug effect. My proposal is a step toward improving the precision with which we select treatments for our patients.
